📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sagility Limited Appoints Genpact Veteran Srinivas Mattapalli as Group CFO
Sagility Limited has appointed Mr. Srinivas Rathnam Mattapalli as its new Group Chief Financial Officer and Key Managerial Personnel, effective February 14, 2026. Mr. Mattapalli is an industry veteran with over 30 years of experience, notably serving as Senior Vice President at Genpact (NYSE: G). His expertise includes managing P&L growth, commercial strategy, and digital transformation for global organizations. This leadership change aims to leverage his extensive background in finance and international business to drive the company's future-ready finance ecosystem.
Key Highlights
Mr. Srinivas Rathnam Mattapalli appointed as Group CFO effective February 14, 2026
Brings over 30 years of experience in finance leadership and business transformation
Former Senior Vice President at Genpact, overseeing the Hi-Tech and Manufacturing vertical
Alumnus of IIM Bangalore and a qualified ICWA professional
Previous experience includes leadership roles at Hindustan Coca-Cola and Colgate-Palmolive
💼 Action for Investors
Investors should view this as a positive development as the company brings in a highly experienced leader from a global peer like Genpact. No immediate action is required, but the market will watch for any strategic financial shifts once he takes office in 2026.
Sagility Appoints Genpact Veteran Srinivas Rathnam Mattapalli as Group CFO
Sagility Limited has appointed Mr. Srinivas Rathnam Mattapalli as Group Chief Financial Officer and Key Managerial Personnel, effective February 14, 2026. With over 30 years of experience, Mattapalli joins from Genpact where he served as Senior Vice President, managing Hi-Tech and Manufacturing verticals. His extensive background includes leadership roles at Hindustan Coca-Cola and Colgate-Palmolive, specializing in P&L growth and digital transformation. This strategic hire is intended to bolster Sagility's financial leadership and operational efficiency.
Key Highlights
Appointment of Srinivas Rathnam Mattapalli as Group CFO effective February 14, 2026
Over 30 years of experience in finance and business transformation at global organizations
Former Senior VP at Genpact (NYSE: G) leading enterprise-wide cost transformation programs
Educational background includes IIM Bangalore (PGDM) and ICWA qualification
💼 Action for Investors
Investors should view this as a positive step in strengthening the executive team with global expertise. Monitor upcoming earnings calls to gauge the new CFO's strategic priorities and financial management style.
Sagility Q3 FY26: Revenue Jumps 35.7% YoY to ₹19,712M; EBITDA Margin Hits 26%
Sagility Limited delivered an exceptional Q3 FY26 with revenue rising 35.7% YoY to ₹19,712 million, supported by a 29.1% constant currency growth. Adjusted EBITDA grew 24.2% to ₹5,125 million, maintaining a strong 26% margin, while 9M FY26 Adjusted PAT saw a significant 44.3% YoY increase to ₹8,236 million. The company is benefiting from the BroadPath acquisition and a strong Medicare Advantage enrollment season, leading to an upward revision in revenue guidance. Management highlighted that exposure to the expiring ACA subsidies is negligible, mitigating regulatory risk.
Key Highlights
Consolidated Q3 revenue reached ₹19,712 million with organic growth at 19.9% in INR terms.
Adjusted PAT for 9M FY26 rose 44.3% YoY to ₹8,236 million due to operational efficiency and lower debt.
Won $30.5 million in ACV during Q3, including a top 10 health insurance company and a regional plan.
Seasonal revenue contribution from Open Enrollment increased to 5.5% for FY26 compared to historical 3%.
Active client base expanded to 81, with 7 of 12 new FY26 logos coming from the mid-market segment.
💼 Action for Investors
Sagility's strong organic growth and successful integration of BroadPath make it a compelling play in the US healthcare outsourcing space. Investors should maintain a positive outlook given the guidance upgrade and the company's ability to navigate US regulatory shifts effectively.
Sagility Q3 FY26 Revenue Surges 35.7% YoY to ₹19,712 Million; Adj. PAT Up 23%
Sagility Limited reported a robust Q3 FY26 with consolidated revenue growing 35.7% YoY to ₹19,712 million, supported by a 29.1% growth in constant currency terms. Adjusted EBITDA for the quarter rose 24.2% YoY to ₹5,125 million with a healthy margin of 26.0%. The company's Adjusted PAT for the nine-month period (9M FY26) showed a significant jump of 44.3% YoY, reaching ₹8,236 million. Notably, the company is successfully diversifying its revenue stream, with the top 10 clients' contribution decreasing from 90.5% in FY25 to 84.6% in the current trailing twelve months.
Key Highlights
Q3 Revenue at ₹19,712 million, up 35.7% YoY (29.1% in constant currency).
Adjusted PAT for Q3 grew 23.0% YoY to ₹3,229 million with a 16.4% margin.
9M FY26 Adjusted PAT increased by 44.3% YoY to ₹8,236 million.
Active client groups increased to 81 from 75 in FY25, reducing top-10 client concentration to 84.6%.
Employee headcount reached 48,522 across 35 delivery centers in 5 countries.
💼 Action for Investors
Investors should take note of the strong organic growth and successful integration of acquisitions like BroadPath which are driving top-line momentum. The improving client diversification and consistent margins make it a strong play in the U.S. healthcare outsourcing space.
Sagility Q3 FY26 Net Profit Rises 23.4% YoY to ₹2,676.5M; Revenue Up 35.6%
Sagility Limited reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue growing 35.6% YoY to ₹19,711.53 million. Net profit for the quarter increased by 23.4% YoY to ₹2,676.56 million, despite an exceptional charge of ₹328.23 million related to the impact of new Labour Codes. The company maintained steady sequential growth with revenue up 18.8% compared to the previous quarter. Operating expenses, particularly employee benefits, rose to ₹12,191.58 million, reflecting the company's expansion and headcount requirements.
Key Highlights
Revenue from operations grew 35.6% YoY to ₹19,711.53 million from ₹14,530.69 million.
Consolidated Net Profit increased 23.4% YoY to ₹2,676.56 million compared to ₹2,169.14 million in Q3 FY25.
Reported an exceptional item of ₹328.23 million on account of the impact of new Labour Codes.
Nine-month (9M FY26) revenue reached ₹51,685.94 million, a significant jump from ₹40,014.42 million in 9M FY25.
Basic and Diluted EPS improved to ₹0.57 for the quarter from ₹0.46 in the year-ago period.
💼 Action for Investors
The company demonstrates robust top-line growth in the healthcare BPM sector; investors should monitor if margin compression from labor costs stabilizes. The stock remains a growth play in the specialized healthcare services outsourcing market.
Sagility Q3 FY26 Revenue Grows 35.7% YoY to ₹19,712 Mn; Adjusted PAT Up 23%
Sagility Limited delivered a robust Q3 FY26 performance with revenue rising 35.7% YoY to ₹19,712 million, supported by 19.9% organic growth. Adjusted EBITDA reached ₹5,125 million at a 26% margin, while 9M FY26 Adjusted PAT saw a significant 44.3% jump to ₹8,236 million. The company added 3 new clients and secured $30.5 million in new business ACV, though DSO increased to 86 days due to higher Q3 volumes. Net debt has been significantly reduced, improving the leverage ratio to 0.37x.
Key Highlights
Q3 FY26 Revenue up 35.7% YoY to ₹19,712 million; 9M FY26 Revenue up 29.2% to ₹51,686 million.
Adjusted PAT grew 23% YoY in Q3 to ₹3,229 million and 44.3% in 9M FY26 to ₹8,236 million.
New business and expansions won in Q3 FY26 represent $30.5 million in potential steady-state ACV.
Net Debt to Adjusted EBITDA ratio improved to 0.37x from 0.71x in FY25, with net debt at ₹6,426 million.
Total headcount reached 48,522 with over 4,100 clinicians and technology heads supporting growth.
💼 Action for Investors
The strong revenue momentum and margin stability make this a positive update, though investors should watch the working capital cycle given the rise in DSO to 86 days. The significant reduction in net debt and strong PAT growth are key positives for long-term valuation.
Sagility Q3 FY26 Net Profit Grows 23.4% YoY to ₹2,677 Mn; Revenue Surges 35.6%
Sagility Limited reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations reaching ₹19,711.53 million, a 35.6% increase year-on-year. Net profit for the period grew by 23.4% YoY to ₹2,676.56 million, despite an exceptional charge of ₹328.23 million related to new Labour Codes. The company's sequential revenue growth was also robust at 18.8% compared to the previous quarter. Earnings per share (EPS) improved to ₹0.57 from ₹0.46 in the corresponding quarter of the previous year.
Key Highlights
Consolidated Revenue from Operations grew 35.6% YoY to ₹19,711.53 million in Q3 FY26.
Net Profit attributable to owners increased 23.4% YoY to ₹2,676.56 million.
Nine-month FY26 revenue reached ₹51,685.94 million, nearly matching the full FY25 revenue of ₹55,699.18 million.
Company recorded a one-time exceptional item of ₹328.23 million due to the impact of new Labour Codes.
Basic and Diluted EPS for the quarter stood at ₹0.57, up from ₹0.53 in the previous quarter.
💼 Action for Investors
Investors should take note of the strong top-line momentum and healthy profit margins in the healthcare BPM segment. The stock remains attractive for long-term investors given the consistent double-digit growth and operational scalability.
Sagility Limited Receives Credit Rating Upgrade and Subsequent Withdrawal by ICRA
Sagility Limited has announced that ICRA Limited upgraded the credit ratings for its long-term and short-term fund-based bank facilities. Following the upgrade, the ratings were withdrawn at the company's request, supported by a No-Objection Certificate (NOC) from the lender. This sequence indicates an improved credit profile prior to the administrative removal of the rating from public tracking. The withdrawal is in accordance with ICRA's established policy and SEBI regulatory requirements.
Key Highlights
ICRA Limited upgraded the credit ratings for long-term and short-term fund-based bank facilities.
Ratings were subsequently withdrawn at the company's request following a No-Objection Certificate from the lender.
The disclosure was made under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The upgrade reflects a strengthening of the company's financial position and creditworthiness.
💼 Action for Investors
Investors should view the rating upgrade as a positive sign of financial health. The withdrawal is likely administrative, but shareholders should monitor for any future changes in the company's debt structure or financing costs.
Sagility Limited Assigned CRISIL A/Stable and A1 Ratings for Rs 300 Crore Bank Facilities
CRISIL Ratings has assigned investment-grade ratings to Sagility Limited's bank loan facilities totaling Rs 300 crore. The company received a long-term rating of 'CRISIL A/Stable' and a short-term rating of 'CRISIL A1'. These ratings indicate a stable outlook and a strong degree of safety regarding the timely servicing of financial obligations. This formal credit assessment provides a benchmark for the company's creditworthiness in the healthcare services sector.
Key Highlights
CRISIL assigned a long-term rating of 'CRISIL A/Stable' for bank facilities.
A short-term rating of 'CRISIL A1' was assigned to the company.
The total bank loan facilities covered under these ratings amount to Rs 300 crore.
The 'Stable' outlook reflects expectations of maintained credit strength over the medium term.
💼 Action for Investors
Investors should take this as a positive sign of the company's financial discipline and creditworthiness. No immediate action is required, but the rating provides a baseline for monitoring future financial health.
Sagility Limited Redeems NCDs Worth ₹110.5 Crore; Pays ₹2.13 Crore Interest
Sagility Limited has completed a partial redemption of 1,105 unsecured, unlisted Non-Convertible Debentures (NCDs) on January 02, 2026. The total principal amount repaid to the debenture holder, Sagility B.V., amounts to ₹110.50 crore. Additionally, the company cleared interest obligations of approximately ₹2.13 crore for the period from October 2025 to January 2026 at an 8% annual rate. This redemption follows the shareholder approval previously obtained in March 2025.
Key Highlights
Redeemed 1,105 unsecured, unlisted NCDs with a face value of ₹10,00,000 each
Total principal amount of ₹110.50 crore paid to debenture holder Sagility B.V.
Interest payment of ₹2.13 crore made for the period Oct 1, 2025, to Jan 1, 2026
Redemption executed at an interest rate of 8% per annum
Action follows shareholder approval via postal ballot dated March 21, 2025
💼 Action for Investors
This deleveraging move is a positive indicator of the company's cash flow strength and commitment to reducing interest-bearing debt. Investors should monitor the impact of reduced interest costs on the company's net profit margins in upcoming quarters.
Sagility Limited Q2 FY25 PAT Surges 69% QoQ to ₹2,508 Million
Sagility Limited has submitted its machine-readable financial results for the quarter and half-year ended September 30, 2025. The company reported a consolidated revenue of ₹16,584.99 million for Q2 FY25, marking a 7.7% growth over the previous quarter. Net profit for the quarter saw a substantial jump to ₹2,508.26 million compared to ₹1,485.59 million in Q1 FY25. The results reflect strong operational performance and sequential growth in the healthcare services segment.
Key Highlights
Consolidated revenue from operations grew 7.7% QoQ to ₹16,584.99 million in Q2 FY25.
Net profit (PAT) for the quarter stood at ₹2,508.26 million, a 68.8% increase over Q1 FY25.
Half-year (H1 FY25) revenue reached ₹31,974.41 million with a total PAT of ₹3,993.85 million.
Basic and Diluted EPS improved to ₹0.53 for the quarter from ₹0.32 in the preceding quarter.
Total assets as of September 30, 2025, increased to ₹1,15,272.97 million, with equity at ₹88,944.57 million.
💼 Action for Investors
Investors should note the strong sequential growth in profitability and revenue, which indicates positive business momentum. The stock remains a key play in the healthcare BPM space, though investors should monitor the high goodwill component on the balance sheet.